Alaunos Therapeutics, Inc. reported earnings results for the third quarter ended September 30, 2022. For the third quarter, the company reported net loss was USD 8.85 million compared to USD 22.73 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.11 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.699 USD | -2.92% |
|
-0.16% | -34.09% |
06-10 | BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO | MT |
05-15 | Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-34.09% | 11.19M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022